AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(Full text of statement. Contact details below.)
BASEL, Sept 2 PRNewswire-AsiaNet - A new study presented at the European Society of Cardiology (ESC) Congress 2002 shows that Diovan(R) (valsartan), the angiotensin II receptor blocker (ARB), is a highly cost-effective treatment for heart failure patients not taking angiotensin-converting-enzyme (ACE) inhibitors, currently the most widely-prescribed drugs for this disease. Based on new data from the landmark Valsartan Heart Failure Trial (Val-HeFT), the study shows that on average, direct treatment costs were USD $929 lower in heart failure patients who took Diovan along with other heart failure treatments prescribed by their physicians, but not ACE inhibitors. The study was presented by Eric Velazquez, MD, Professor of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
Val-HeFT previously established that Diovan significantly improves mortality by 33 per cent and reduces hospitalisations for heart failure by 57 per cent in…
Source: HighBeam Research, NEW DATA SHOWS DIOVAN COST-EFFECTIVE IN TREATING HEART PATIENTS.